Curesponse Secures $6M Series A for Breakthrough Precision Medicine
- Wednesday, June 10, 2020, 7:10
- Business
- Add a comment
– Curesponse is a cancer precision medicine company whose platform, cResponse, accurately and quickly predicts a patient’s response to cancer treatment. – The company has raised $6M from investors including NCL Technology Ventures (UK) and aMoon (Israel) to facilitate scaling of clinical…
About the Author
adminasapcorp has written 41552 stories on this site.